K. Steplewski

发表

The Orphan G Protein-coupled Receptors GPR41 and GPR43 Are Activated by Propionate and Other Short Chain Carboxylic Acids*

S. Dowell, F. Marshall, M. Wigglesworth, 2003, The Journal of Biological Chemistry.

Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators

N. Aiyar, Z. Ao, D. Johns, 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases

R. Greil, E. Winer, N. Lin, 2011, Journal of Neuro-Oncology.

Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER 2-Positive Breast Cancer

R. Greil, E. Winer, Minetta C. Liu, 2009 .

Site-Specific Atherogenic Gene Expression Correlates With Subsequent Variable Lesion Development in Coronary and Peripheral Vasculature

R. Wilensky, M. Lu, E. Mohler, 2008, Arteriosclerosis, thrombosis, and vascular biology.

In Vivo Activation of Peroxisome Proliferator-Activated Receptor-δ Protects the Heart from Ischemia/Reperfusion Injury in Zucker Fatty Rats

W. Bao, S. Nerurkar, R. Willette, 2008, Journal of Pharmacology and Experimental Therapeutics.

PPARdelta activation normalizes cardiac substrate metabolism and reduces right ventricular hypertrophy in congestive heart failure.

C. Doe, R. Willette, S. Lenhard, 2007, Journal of cardiovascular pharmacology.

Molecular Identification of High and Low Affinity Receptors for Nicotinic Acid*

S. Dowell, F. Marshall, P. Murdock, 2003, The Journal of Biological Chemistry.

AXOR12, a Novel Human G Protein-coupled Receptor, Activated by the Peptide KiSS-1*

P. Emson, R. Faull, J. Chambers, 2001, The Journal of Biological Chemistry.

Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

R. Greil, E. Winer, Minetta C. Liu, 2009, Clinical Cancer Research.

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.

Joon-Oh Park, B. Somer, N. Le, 2014, European journal of cancer.

Quantitative analysis of orphan G protein-coupled receptor mRNAs by TaqMan Real-Time PCR: G2A and GPR4 lysophospholipid receptor expression in leukocytes and in a rat myocardial infarction-heart failure model.

P. Murdock, Z. Ao, D. Johns, 2005, Methods in molecular biology.

Quantitative mRNA analysis of serotonin 5-HT4 receptor isoforms, calcium handling proteins and ion channels in human atrial fibrillation.

A. Mugelli, F. Lezoualc’h, R. Fischmeister, 2007, Biochemical and biophysical research communications.

Localisation of NMU1R and NMU2R in human and rat central nervous system and effects of neuromedin-U following central administration in rats

J. Hagan, H. Sarau, P. Murdock, 2004, Psychopharmacology.

PPARδ Activation Normalizes Cardiac Substrate Metabolism and Reduces Right Ventricular Hypertrophy in Congestive Heart Failure

C. Doe, R. Willette, S. Lenhard, 2007 .

Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression‐free survival in patients with HER2‐positive metastatic breast cancer receiving lapatinib monotherapy

W. Carney, K. Steplewski, A. Lipton, 2011, Cancer.

Predominance of a Proinflammatory Phenotype in Monocyte-Derived Macrophages From Subjects With Low Plasma HDL-Cholesterol

M. Jaye, R. S. Kiss, Y. Marcel, 2007, Arteriosclerosis, thrombosis, and vascular biology.

Neuromedin Elicits Cytokine Release in Murine Th2-Type T Cell Clone D10.G4.1

H. Sarau, J. Foley, N. Aiyar, 2004, The Journal of Immunology.

Functional characterization of an orphan nuclear receptor, Rev-ErbAalpha, in chondrocytes and its potential role in osteoarthritis.

S. Kumar, J. Connor, K. Steplewski, 2006, Arthritis and rheumatism.

Discovery of substituted maleimides as liver X receptor agonists and determination of a ligand-bound crystal structure.

Angela Smallwood, Ping Wang, David Haigh, 2005, Journal of medicinal chemistry.

A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.

Joon-Oh Park, B. Somer, N. Le, 2013 .